ArticleJournal of inflammation research2025
TNF/NF-κB Signaling Pathway is Involved in Mechanisms of Tongluo Decoction on Rat Models with Sequelae of Pelvic Inflammatory Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Astragaloside IV AlleviatesAntioxidants (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Traditional Chinese medicine can produce strong therapeutic activities for sequelae of pelvic inflammatory disease (SPID). This study aimed to investigate the efficacy and protective mechanisms of Tongluo Decoction (TLD) in the treatment of SPID. Patients and Methods: The damage-protective and inflammation-inhibitory effects of TLD on SPID were investigated in rat models. The possible targets of TLD against SPID were predicted using network pharmacology. The hub targets were tested in SPID rat models. Rescue experiments were conducted in human endometrial epithelial cells (HEECs). Detection of necroptosis was used the flow cytometry. ELISA was used for the quantification of inflammatory cytokines. Protein levels were detected using a Western blot assay. Results: TLD had a protective effect against uterus tissue damage caused during SPID. TLD inhibited the levels of adhesion cytokines (VEGF and TGF-β1), the tight junction proteins (ZO-1 and occludin), and inflammatory cytokines (TNF-α and IL-6). TNF, IKBKB, and NFKB1 were predicted as hub targets for TLD against SPID. TLD inhibited necroptosis of HEECs via TNF, IKBKB, and NFKB1. TLD inhibited the ratio of CD86+ M1 macrophages after differentiation induction of THP-1. Conclusion: The therapeutic effects of TLD for SPID may be the result of a dual action on inflammation and necroptosis, via TNF, IKBKB, and NFKB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.